Guanidinopropionic acid (GPA) increases AMPK activity, mitochondrial function and biogenesis in muscle and improves physiological function, for example during aging. Mitochondrial dysfunction is a major contributor to the pathogenesis of Parkinson's disease. Here we tested whether GPA prevents neurodegeneration of the nigrostriatal dopamine system in MPTP-treated mice. Mice were fed a diet of 1% GPA or normal chow for 4 weeks and then treated with either MPTP or saline. Indices of nigrostriatal function were examined by HPLC, immunohistochemistry, stereology, electron microscopy and mitochondrial respiration. MPTP intoxication decreased TH neurons in the SNpc of normal chow-fed mice; however GPA-fed mice remarkably exhibited no loss of TH neurons in the SNpc. MPTP caused a decrease in striatal dopamine of both normal chow-and GPAfed mice, although this effect was significantly attenuated in GPA-fed mice. GPA-fed mice showed increased AMPK activity, mitochondrial respiration and mitochondrial number in nigrostriatal TH neurons, suggesting that the neuroprotective effects of GPA involved AMPK-dependent increases in mitochondrial function and biogenesis. MPTP treatment produced a decrease in mitochondrial number and volume in normal chow-fed mice but not GPA-fed mice. Our results show the neuroprotective properties of GPA in a mouse model of Parkinson's disease are partially mediated by AMPK and mitochondrial function. Mitochondrial dysfunction is a common problem in neurodegeneration and thus GPA may slow disease progression in other models of neurodegeneration.
Introduction
Parkinson's disease (PD) is the second most common neurodegenerative disorder next to Alzheimer's disease and cardinal features of PD include motor dysfunction such as rigidity, resting tremor, postural instability and bradykinesia. These debilitating symptoms manifest due to the massive loss of dopamine in the striatum, the nerve terminal region of dopamine neurons located in the substantia nigra pars compacta (SNpc). At present there are only a few known monogenic mutations accelerating the onset of PD; therefore most cases are considered sporadic and develop as a complex polygenic interaction with age and environment.
Mitochondrial dysfunction is well characterized as a major contributor to the onset of PD (Abou-Sleiman et al., 2006) and human PD patients show a mitochondrial complex 1 deficiency (Schapira et al., 1989) . Indeed, the most common PD model in mice, MPTP, is a complex 1 inhibitor. Impaired mitochondrial mechanisms contribute to PD by decreasing ATP generating potential (Gispert et al., 2009) , 2006) . In fact, many monogenic mutations that promote nigral degeneration and parkinsonism in humans, such as parkin, DJ1, PTEN-induced kinase 1, all manifest mitochondrial pathologies (Clark et al., 2006; Palacino et al., 2004; Zhang et al., 2005) . Thus, the most accepted mode of nigral degeneration, whether it is monogenic mutation or a polygenic interaction with age and environment, involves mitochondrial pathology.
Because of the importance of mitochondria in maintaining bioenergetic status and neuronal function in PD, factors positively regulating mitochondrial function are likely to slow disease progression. We Neurobiology of Disease 43 (2011) 152-162 
